Stocks declined Tuesday amid increased conflict in the Middle East and as the U.S. moved to curb inversion deals.» Read More
FRANKFURT, Germany— German drug company Merck says it has agreed to buy St. Louis- based chemical firm Sigma-Aldrich Corp. for $17 billion in a deal Merck says will strengthen its business in chemicals and laboratory equipment.
PARIS, Sept 18- French cancer immunotherapy specialist OSE Pharma has registered with market regulator AMF for an initial public offering aimed at financing late-stage trials of its Texopi drug for the most common form of lung cancer, the company said on Thursday.
NEW YORK— Merck is licensing an experimental psoriasis drug to Indian drugmaker Sun Pharmaceuticals, the companies said Wednesday. The Whitehouse Station, New Jersey, company will also get royalties on sales if the drug is approved. Shares of Merck& Co. slipped 41 cents to $59.58 in morning trading.
*Lilly to partner on AstraZeneca's BACE inhibitor drug. LONDON, Sept 16- AstraZeneca has signed a partnership deal with U.S. rival Eli Lilly that could earn the British company up to $500 million if a promising- but risky- experimental Alzheimer's drug proves successful.
Sept 15- Merck& Co said it will seek U.S. approval next year for its long-delayed experimental osteoporosis drug, odanacatib, after it proved effective in a late-stage trial but was associated with rare thigh-bone fractures seen with standard treatments.
Sept 15- Epirus Biopharmaceuticals Inc said India's drug regulator has approved its copy of a top-selling arthritis treatment, paving the way for its launch in the country early next year.
U.S. stocks closed down on Friday, breaking five weeks of consecutive gains as investors awaited the Federal Reserve's announcement next Wednesday.
JOHANNESBURG, Sept 10- Aspen Pharmacare is to sell the rights to market a blood clot drug in the United States to rival Mylan Inc for up to $300 million, it said on Wednesday, a move that would help Africa's top generic drugmaker pay down debt.
Vamil Divan, Senior Analyst, U.S. Pharmaceuticals at Credit Suisse, discusses news that Bristol-Myers Squibb and Ono Pharmaceutical are suing Merck over the Keytruda cancer drug.
Gilead is already among the 10 best performers in the Nasdaq 100 this year. So can anything slow this behemoth down? If you ask the analysts, it sounds unlikely.
U.S. stocks closed mixed on Wednesday, coming off morning highs amid economic reports and central bank news.
*Zoetis explores international markets for product. CHICAGO, Sept 3- Zoetis Inc has received a conditional license from the U.S. Department of Agriculture for its vaccine against a deadly piglet virus and will begin selling it this month in the United States, the company said on Wednesday.
CHICAGO, Sept 3- Zoetis Inc, the world's largest animal-health company, has received a conditional license from the U.S. Agriculture Department for its vaccine against a deadly piglet virus and will begin selling it this month in the United States, the company said on Wednesday.
As tensions between Hong Kong and Beijing increase, multinational firms are seeing more stability in Singapore and expanding their outlook.
*AstraZeneca shares up 2 percent. LONDON, Aug 29- Hopes for AstraZeneca's promising cancer drug pipeline were boosted on Friday by news the company had moved its immuno-oncology medicine MEDI-4736 into a mid-stage study in colorectal cancer.
Some of the names on the move ahead of the open.
The "Fast Money" traders share their final trades of the day.
Some of Tuesday's midday movers:
Aug 26- Pfizer Inc said Tuesday it will test its Xalkori lung cancer drug with Merck& Co's experimental immunotherapy pembrolizumab, in hopes the combination will improve the outcomes for patients taking the approved Pfizer therapy. The largest U.S. drugmakers said the combination study will begin in 2015 and be conducted by Pfizer.
Aug 26- Pfizer Inc said Tuesday it will test its Xalkori lung cancer drug with Merck& Co's experimental immunotherapy pembrolizumab, in the hopes the combination will improve the outcomes for patients taking the approved Pfizer therapy. The largest U.S. drugmakers said the combination study will begin in 2015 and be conducted by Pfizer.